Clinical drivers for imaging testing in nonmetastatic castration-resistant prostate cancer: May they be optimized?—Data of “IDENTIFICA” study.

318Background: Metastases (M+) detection is a critical event in non-metastatic castration-resistant prostate cancer (nmCRPC), as it entails a change in PC management and is a potential surrogate for survival at this stage. PSA doubling time (PSA-DT) has been described as a prognostic factor to develop M+. However, there could be other relevant factors to raise suspicion of progression in nmCRPC patients. The “IDENTIFICA” study tries to describe disease characteristics and clinical drivers that make physicians suspect the presence of M+ in nmCRPC patients in clinical practice in Spain. Methods: Observational, transversal, multicenter study. nmCRPC patients with physician’s suspiction of M+ were selected. Imaging tests to rule out metastases were requested; clinical drivers were described, along with clinical data related to prostate cancer (PC). Results: 197 nmCRPC patients were recruited (Jan-Jun 2018). Median age was 81.3 years. Median time from the onset of androgen deprivation therapy (ADT) to CRPC was...